SITE008-0448

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-09-10

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 29); relationship: Y

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-08 (study day 44); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-11-24 (study day 60); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-27 (study day 63); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 96); relationship: N

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-03-28 (study day 185); relationship: N

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-05-10 (study day 228); relationship: N

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-07-16 (study day 295); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-08-24 (study day 334); relationship: not assessed

Data queries

No data queries.